ACIU Operating Margin from 2010 to 2024
| ACIU Stock | USD 2.73 0.02 0.74% |
Check AC Immune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AC Immune's main balance sheet or income statement drivers, such as Interest Expense of 167.2 K, Selling General Administrative of 8.3 M or Total Revenue of 20 M, as well as many indicators such as Price To Sales Ratio of 38.71, Dividend Yield of 0.0 or PTB Ratio of 2.11. ACIU financial statements analysis is a perfect complement when working with AC Immune Valuation or Volatility modules.
ACIU | Operating Margin |
Latest AC Immune's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of AC Immune over the last few years. It is AC Immune's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AC Immune's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.29 % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
ACIU Operating Margin Regression Statistics
| Arithmetic Mean | (4.00) | |
| Geometric Mean | 1.88 | |
| Coefficient Of Variation | (150.81) | |
| Mean Deviation | 4.12 | |
| Median | (1.33) | |
| Standard Deviation | 6.03 | |
| Sample Variance | 36.33 | |
| Range | 18.4808 | |
| R-Value | (0.53) | |
| Mean Square Error | 28.06 | |
| R-Squared | 0.28 | |
| Significance | 0.04 | |
| Slope | (0.72) | |
| Total Sum of Squares | 508.55 |
ACIU Operating Margin History
About AC Immune Financial Statements
AC Immune shareholders use historical fundamental indicators, such as Operating Margin, to determine how well the company is positioned to perform in the future. Although AC Immune investors may analyze each financial statement separately, they are all interrelated. The changes in AC Immune's assets and liabilities, for example, are also reflected in the revenues and expenses on on AC Immune's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland. AC Immune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ACIU Stock Analysis
When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.